Download PDF
Thromb Haemost 1998; 79(04): 731-735
DOI: 10.1055/s-0037-1615054
Rapid Communication
Schattauer GmbH

Polymorphism of Platelet Membrane Glycoprotein IIIa: Human Platelet Antigen 1b (HPA-1b/PlA2) Is an Inherited Risk Factor for Premature Myocardial Infarction in Coronary Artery Disease

Rainer B. Zotz
1   From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany
,
Bernhard R. Winkelmann
2   From the Department of Cardiology, Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany
,
Markus Nauck
3   From the Division of Clinical Chemistry, Albert Ludwigs University, Freiburg, Germany
,
Günther Giers
1   From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany
,
Beate Maruhn-Debowski
1   From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany
,
Winfried März
3   From the Division of Clinical Chemistry, Albert Ludwigs University, Freiburg, Germany
,
Rüdiger E. Scharf
1   From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany
› Author AffiliationsSupported in part by a grant (Sch 358/1-3) from the Deutsche Forschungsgemeinschaft, Bonn, Germany
Further Information

Publication History

Received 28 August 1997

Accepted after revision 02 December 1997

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Conflicting results of an association between the human platelet antigen 1b (HPA-1b or PlA2) allele and the risk of myocardial infarction and coronary artery disease have been reported. To assess the reason for this discrepancy, we determined the HPA-1 genotype in 298 men who had undergone coronary angiography, including 124 individuals with myocardial infarction, 83 individuals with coronary artery disease but no history of myocardial infarction, and 91 control patients. Among patients with acute or recent onset myocardial infarction (<1 year), the prevalence of HPA-1b was higher than among patients with coronary artery disease but without myocardial infarction (33 percent vs. 14 percent, p = 0.016). In patients under 60 years of age this difference was even more pronounced (45 percent vs. 15 percent, p = 0.003). Unlike conventional risk factors HPA-1b does not represent a risk factor for coronary artery disease itself but appears to be associated with increased platelet thrombogenicity.

 

  • References

  • 1 Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary artery disease. N Engl J Med 1986; 315: 983-9.
    CrossrefPubMedGoogle Scholar
  • 2 Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram. Quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986; 8: 1380-6.
    CrossrefPubMedGoogle Scholar
  • 3 DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-23.
    CrossrefPubMedGoogle Scholar
  • 4 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
    CrossrefPubMedGoogle Scholar
  • 5 Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
    CrossrefPubMedGoogle Scholar
  • 6 Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: a multi functional adhesion receptor. Haematologica 1992; 77: 162-8.
    PubMedGoogle Scholar
  • 7 Nurden AT. Polymorphism of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemost 1995; 74: 345-51.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Scharf RE. Molecular basis and clinical aspects of hereditary megakaryocyte and platelet membrane glycoprotein disorders. Haemostaseologie 1996; 16: 114-38.
    PubMedGoogle Scholar
  • 9 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
    PubMedGoogle Scholar
  • 10 Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-9.
    CrossrefPubMedGoogle Scholar
  • 11 Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991; 84: 708-11.
    CrossrefPubMedGoogle Scholar
  • 12 Verheut FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267-70.
    CrossrefPubMedGoogle Scholar
  • 13 The RISC Group.. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
    CrossrefPubMedGoogle Scholar
  • 14 Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia: the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 1992; 340: 497-501.
    CrossrefPubMedGoogle Scholar
  • 15 Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-5.
    CrossrefPubMedGoogle Scholar
  • 16 Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69.
    CrossrefPubMedGoogle Scholar
  • 17 Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab´)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-9.
    CrossrefPubMedGoogle Scholar
  • 18 Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-80.
    CrossrefPubMedGoogle Scholar
  • 19 Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab’)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21: 393-405.
    CrossrefPubMedGoogle Scholar
  • 20 The EPIC Investigators.. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
    CrossrefPubMedGoogle Scholar
  • 21 Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley D, Worley SJ, Weisman HF, Califf RM, Topol EJ. for the EPIC investigators. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol 1996; 28: 849-55.
    CrossrefPubMedGoogle Scholar
  • 22 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
    CrossrefPubMedGoogle Scholar
  • 23 Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386-404.
    PubMedGoogle Scholar
  • 24 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
    CrossrefPubMedGoogle Scholar
  • 25 Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1071-2.
    CrossrefPubMedGoogle Scholar
  • 26 Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1072-3.
    PubMedGoogle Scholar
  • 27 Ridker PM, Hennekens CH, Schmitz C, Stampfer M, Lindpaintner K. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
    CrossrefPubMedGoogle Scholar
  • 28 Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-10.
    PubMedGoogle Scholar
  • 29 Herrmann SM, Poirer O, Marques-Vidal P, Evans A, Arveiler D, Luc G, Emmerich J, Cambien F. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Austen WG, Edwards JE, Frye RL, Gensini CG, Gott VL, Griffith LS. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51 Suppl 5-40.
    CrossrefPubMedGoogle Scholar
  • 31 Winkelmann BR, Nauck M, Klein B, Russ AP, Böhm BO, Siekmeier R, Ihnken K, Verho M, Groß W, März W. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 1996; 125: 19-25.
    CrossrefPubMedGoogle Scholar
  • 32 Zotz RB, Giers G, Maruhn-Debowski B, Scharf RE. Genetic typing of human platelet antigen 1 (HPA-1) by oligonucleotide ligation assay in a specific and reliable semi-automated system. Brit J Haematol 1997; 96: 198-203.
    CrossrefPubMedGoogle Scholar
  • 33 Nurden AT. Polymorphisms of the platelet receptors as risk factors in coronary thrombosis. Eur Heart J 1996; 17: 1293-1294.
    PubMedGoogle Scholar
  • 34 Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.
    PubMedGoogle Scholar